I-Mab to Release Q3 2024 Financial Results on November 14, 2024
2024-11-01
I-Mab Biopharma
HaiPress
ROCKVILLE,Md.,Oct. 31,2024 -- I-Mab (NASDAQ: IMAB) (the "Company"),a US-based,global biotech company,exclusively focused on the development of highly differentiated immunotherapies for the treatment of cancer,today announced that it plans to release financial results for the third quarter ended September 30,2024,on Thursday,November 14,pre-market Eastern Time.
The Company will not host a conference call to discuss its third quarter 2024 financial results. The Company intends to host an investor update call in conjunction with its 2024 full-year financial results to discuss its clinical pipeline,corporate strategy,and objectives. Information about financial results,conference calls,webcasts,and other information is posted on the Company's website.
AboutI-Mab
I-Mab (NASDAQ: IMAB) is a US-based,exclusively focused on the development of highly differentiated immunotherapies for the treatment of cancer.
I-Mab has established operations in Rockville,Maryland,and Short Hills,New Jersey.For more information,please visithttps://www.i-mabbiopharma.comand followus onLinkedInandX.
I-Mab Investor & Media Contacts
Tyler Ehler
Senior Director,Investor Relations
IR@imabbio.com
Newest
-
Se celebra la 68ª sesión de la Comisión de Estupefacientes de las Naciones Unidas: China, un participante activo en la lucha global contra las drogas
-
AXES TREE LLC Launches AXES USDT: Blockchain Meets Advertising
-
Laika Officially Launches the MMS Token Swap Program: Premium Members Unite to Drive a New Market Era
-
"Daily Get·Lottery fund trust services (formerly Cola Financial) and มิราเคิล กรุ๊ป จำกัด reached a strategic cooperation in lottery fund trust to jointly usher in a new era of sunshine in the Asia-Pacific lottery market"